GlobeNewswire, Inc.

YTD’26 Net Income of $25.6M, +85.9% from YTD’25 YTD’26 Adjusted EBITDA of $114.7M, +21.9% from YTD’25 Full-Year 2026 Guidance Raised to Above High End for All Key Financial Metrics Expands VBC Footprint with Acquisition of American Choice...

GlobeNewswire, Inc.

On track to complete lonvo-z commercial readiness efforts in advance of March 10, 2027 PDUFA date New lonvo-z patient perspectives and Phase 1/2 durability data to be included in investor webcast and multiple presentations next week at ACAAI 2026...

GlobeNewswire, Inc.

ALAMEDA, Calif., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Scribe Therapeutics Inc. (“Scribe Therapeutics” or “the Company”) (Nasdaq: SCTX), a clinical-stage biotechnology company engineering purpose-built in vivo CRISPR technologies designed to extend...

GlobeNewswire, Inc.

– Initiated the RECEPTIVE-CD1 Phase 2b clinical trial of SL-325 in Crohn’s disease; 12-week induction data expected in the first half of 2028 – – Announced RECEPTIVE-HS1 Phase 2 clinical trial of SL-325 in hidradenitis suppurativa; trial...

GlobeNewswire, Inc.

Advancing abdakibart toward a registrational Phase 3 program in hidradenitis suppurativa, with initiation planned for the first half of 2027 Advancing AVTX-010, a next-generation, long-acting anti-IL-1β antibody, toward an Investigational New Drug...

GlobeNewswire, Inc.

Q2 Revenue of $336.3 million, up 22.7% versus prior year Q2 Diluted EPS of $0.53; Adjusted Diluted EPS of $1.13, compared to prior year Adjusted Diluted EPS of $1.07 The Breathe Right® portfolio and LaCorium acquisitions performed as expected in...